{
    "info": {
        "nct_id": "NCT04539808",
        "official_title": "NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer",
        "inclusion_criteria": "* Ability to understand and the willingness to sign a written informed consent document\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Cytologic or histologic proof pancreatic ductal carcinoma is required prior to study entry\n\n  * If a biopsy (e.g., endoscopic ultrasound [EUS]-guided fine needle aspiration [FNA]) is planned per standard of care, the participant may be asked to consent to the additional collection of tumor tissue for research\n* No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis computed tomography (CT) scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) within the 45-day window of study entry or prior to the one cycle of standard of care (SOC) administered before study entry, which is consistent with the standard of care\n\n  * Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, baseline radiographic imaging performed per institutional guidelines prior to SOC chemotherapy treatment may be used per investigator discretion to fulfill baseline radiographic imaging criteria even if performed > 45 days prior to official study entry.\n* Diagnostic staging laparoscopy is not required for study eligibility\n\n  * If staging laparoscopy is planned per standard of care, the participant may be asked to consent to the collection of tumor tissue for research\n* At time of screening, per National Comprehensive Cancer Network (NCCN) criteria, must have either:\n\n  * Resectable pancreatic ductal adenocarcinoma (PDAC), defined as no arterial tumor contact (celiac axis [CA], superior mesenteric artery [SMA], or common hepatic artery [CHA]), or\n  * Node positive disease as defined by CT, MRI, or EUS imaging, or\n  * Borderline resectable PDAC, defined as:\n\n    * For tumors of the head or uncinate process:\n\n      * Solid tumor contact with the superior mesenteric vein (SMV) or portal vein of > 180 degrees with contour irregularity of the vein or thrombosis of the vein, but with suitable vessel proximal and distal to the site of involvement, allowing for safe and complete resection and vein reconstruction\n      * Solid tumor contact with the inferior vena cava\n      * Solid tumor contact with the common hepatic artery without extension to the celiac axis or hepatic artery bifurcation, allowing for safe and complete resection and reconstruction\n      * Solid tumor contact with the SMA =< 180 degrees\n      * Solid tumor contact with variable anatomy (e.g., accessory right hepatic artery, replaced right hepatic artery, replaced common hepatic artery, and the origin of replaced or accessory artery), and the presence and degree of tumor contact should be noted if present, as it may affect surgical planning\n    * For tumors of the body/tail:\n\n      * Solid tumor contact with the celiac axis of =< 180 degrees\n      * Solid tumor contact with the celiac axis >180 degrees without involvement of the aorta and with an intact and uninvolved gastroduodenal artery, thereby permitting a modified Appleby procedure (although some members of the consensus committee preferred this criterion to be in the unresectable category)\n  * Locally-advanced, unresectable disease as defined by NCCN guidelines as follows:\n\n    * Tumors of the head with SMA >= 180 degrees, or any celiac abutment, unreconstractable SMV or portal occlusion, or aortic invasion or encasement\n    * Tumors of the body with SMA or celiac encasement 180 degrees, unreconstractable SMV or portal occlusion, or aortic invasion\n    * Tumors of the tail with SMA or celiac encasement >= 180 degrees\n    * Irrespective of location, all tumors with evidence of nodal metastasis outside of the resection field that are considered unresectable\n* Must be deemed fit to undergo planned curative resection as determined by institutional standards\n* No history of previous chemotherapy for pancreatic cancer. At the discretion of the principal investigator (PI), patient that have received no more than 1 month of systemic chemotherapy (e.g., mFOLFIRINOX), per standard of care, for the treatment of their PDAC may be eligible to participate\n* For participants who will get INV losartan, baseline systolic blood pressure (BP) > 100 mm Hg taken as the average of 3 blood pressure readings\n* Hemoglobin > 9 g/dL with no blood transfusion within 28 days of starting treatment (prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)\n\n  * Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment\n* Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 cells/mm^3) (prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)\n\n  * Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment\n  * May be waived on a case-by-case basis for patient populations recognized to have normal baseline values below this level\n* Platelet count >= 100 x 10^9/L (> 100,000 per mm^3) (at time of registration and within 4 weeks prior to initiating study therapy)\n* Creatinine =< 1.5 mg/dL OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min/1.73 m^2 for participants with creatinine levels > 1.5 x institutional upper limit of normal (ULN) prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)\n\n  * Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment\n  * Creatinine clearance should be calculated per institutional standard. For participants with a baseline calculated creatinine clearance below normal institutional laboratory values, a measured baseline creatinine clearance should be determined. Individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis\n* Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN); or =< 2 x ULN or 2 down-trending values for individuals who have undergone biliary stenting prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)\n\n  * Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN, OR two consecutive down-trending values for individuals who have undergone biliary stenting prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)\n\n  * Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to initiating study therapy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female participants of childbearing potential agree to use adequate methods of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy\n\n  * Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause\n* Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy\n* Male patients must use a condom during treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male participant should also use a highly effective form of contraception if they are of childbearing potential\n* Participants currently receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) will remain eligible for study participation. In such cases, losartan will not be assigned as part of the study intervention. These participants will continue to receive their ACE inhibitor or ARB per standard-of-care. The ACE inhibitor or ARB type should be recorded as a concomitant medication (including dose and frequency)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of previous chemotherapy (other than no more than one cycle of standard systemic chemotherapy), targeted/biologic therapy, or radiation therapy for the treatment of their PDAC\n* Evidence of metastasis to distant organs (liver, peritoneum, lung, others)\n* Any other active malignancy or prior history of malignancy with less than a 90% cure rate in the judgement of the investigators\n* Medical co-morbidities that are deemed to make risk of surgery unacceptably high as determined by institutional standards\n* Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Patients with cardiovascular conditions that are well-controlled in the clinical judgement of the treating oncologist are eligible to participate\n* Recent major surgery (excluding laparoscopy) within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Patients must be recovered from effects of surgery\n* Concomitant use of other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy [hormone replacement therapy is acceptable]), not otherwise allowed in this study. Note: participation in other trials for supportive cancer care (e.g., cancer-related cachexia) interventions is permitted per PI discretion.\n* Participants with a history of hypersensitivity reactions to study agents or their excipients. In cases of losartan hypersensitivity, losartan will be omitted and patient may still be eligible to participate\n* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial therapy\n* Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would: interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring adverse events (AEs), or compromise the ability of the patient to give written informed consent\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Solid tumor contact with the celiac axis of =< 180 degrees",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with the celiac axis of =< 180 degrees",
                    "criterion": "solid tumor contact with the celiac axis",
                    "requirements": [
                        {
                            "requirement_type": "degree of contact",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause",
            "criterions": [
                {
                    "exact_snippets": "Participants of childbearing potential ... have not been surgically sterilized",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have not been free from menses for > 1 year without an alternative medical cause",
                    "criterion": "menstrual status",
                    "requirements": [
                        {
                            "requirement_type": "free from menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        },
                        {
                            "requirement_type": "alternative medical cause",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For participants who will get INV losartan, baseline systolic blood pressure (BP) > 100 mm Hg taken as the average of 3 blood pressure readings",
            "criterions": [
                {
                    "exact_snippets": "participants who will get INV losartan",
                    "criterion": "INV losartan treatment group",
                    "requirements": [
                        {
                            "requirement_type": "group membership",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "baseline systolic blood pressure (BP) > 100 mm Hg taken as the average of 3 blood pressure readings",
                    "criterion": "baseline systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "average of 3 blood pressure readings"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnostic staging laparoscopy is not required for study eligibility",
            "criterions": [
                {
                    "exact_snippets": "Diagnostic staging laparoscopy is not required for study eligibility",
                    "criterion": "diagnostic staging laparoscopy",
                    "requirements": [
                        {
                            "requirement_type": "requirement for eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100 x 10^9/L (> 100,000 per mm^3) (at time of registration and within 4 weeks prior to initiating study therapy)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100 x 10^9/L (> 100,000 per mm^3) (at time of registration and within 4 weeks prior to initiating study therapy)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "per mm^3"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at time of registration",
                                "within 4 weeks prior to initiating study therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No history of previous chemotherapy for pancreatic cancer. At the discretion of the principal investigator (PI), patient that have received no more than 1 month of systemic chemotherapy (e.g., mFOLFIRINOX), per standard of care, for the treatment of their PDAC may be eligible to participate",
            "criterions": [
                {
                    "exact_snippets": "No history of previous chemotherapy for pancreatic cancer",
                    "criterion": "previous chemotherapy for pancreatic cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no more than 1 month of systemic chemotherapy (e.g., mFOLFIRINOX), per standard of care, for the treatment of their PDAC",
                    "criterion": "systemic chemotherapy for PDAC",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumors of the body with SMA or celiac encasement 180 degrees, unreconstractable SMV or portal occlusion, or aortic invasion",
            "criterions": [
                {
                    "exact_snippets": "SMA or celiac encasement 180 degrees",
                    "criterion": "SMA or celiac encasement",
                    "requirements": [
                        {
                            "requirement_type": "degree of encasement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unreconstractable SMV or portal occlusion",
                    "criterion": "SMV or portal occlusion",
                    "requirements": [
                        {
                            "requirement_type": "reconstructability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic invasion",
                    "criterion": "aortic invasion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to initiating study therapy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative urine or serum pregnancy test within 72 hours prior to initiating study therapy",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine",
                                "serum"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours prior to initiating study therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment",
            "criterions": [
                {
                    "exact_snippets": "participants who enroll on trial after having received up to 1 month of standard of care chemotherapy",
                    "criterion": "prior standard of care chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "labs prior to initiation of SOC chemotherapy treatment may be used ... to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study entry",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to SOC chemotherapy",
                            "expected_value": "prior to initiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine =< 1.5 mg/dL OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min/1.73 m^2 for participants with creatinine levels > 1.5 x institutional upper limit of normal (ULN) prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine =< 1.5 mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "measured or calculated creatinine clearance ... >= 30 mL/min/1.73 m^2 for participants with creatinine levels > 1.5 x institutional upper limit of normal (ULN)",
                    "criterion": "creatinine clearance (or GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m^2"
                            }
                        },
                        {
                            "requirement_type": "applicable_if",
                            "expected_value": "serum creatinine > 1.5 x institutional upper limit of normal (ULN)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential agree to use adequate methods of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use adequate methods of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use of contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from first dose of study therapy through 30 days after the last dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment",
            "criterions": [
                {
                    "exact_snippets": "participants who enroll on trial after having received up to 1 month of standard of care chemotherapy",
                    "criterion": "prior standard of care chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "labs prior to initiation of SOC chemotherapy treatment may be used ... to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study entry",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to SOC chemotherapy",
                            "expected_value": "prior to initiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Node positive disease as defined by CT, MRI, or EUS imaging, or",
            "criterions": [
                {
                    "exact_snippets": "Node positive disease as defined by CT, MRI, or EUS imaging",
                    "criterion": "node positive disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_method",
                            "expected_value": [
                                "CT",
                                "MRI",
                                "EUS imaging"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Solid tumor contact with the SMA =< 180 degrees",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with the SMA =< 180 degrees",
                    "criterion": "solid tumor contact with the SMA",
                    "requirements": [
                        {
                            "requirement_type": "angle",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 cells/mm^3) (prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 cells/mm^3) (prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1000,
                                "unit": "cells/mm^3"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "prior to the one month of standard of care chemotherapy allowed by the protocol",
                                "within 4 weeks of screening"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN); or =< 2 x ULN or 2 down-trending values for individuals who have undergone biliary stenting prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN)",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum bilirubin ... =< 2 x ULN or 2 down-trending values for individuals who have undergone biliary stenting prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening",
                    "criterion": "serum bilirubin (in individuals with prior biliary stenting)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "trend",
                            "expected_value": "2 down-trending values"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumors of the tail with SMA or celiac encasement >= 180 degrees",
            "criterions": [
                {
                    "exact_snippets": "Tumors of the tail",
                    "criterion": "tumor location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "tail"
                        }
                    ]
                },
                {
                    "exact_snippets": "SMA or celiac encasement >= 180 degrees",
                    "criterion": "arterial encasement",
                    "requirements": [
                        {
                            "requirement_type": "artery",
                            "expected_value": [
                                "SMA",
                                "celiac"
                            ]
                        },
                        {
                            "requirement_type": "encasement_degree",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For tumors of the body/tail:",
            "criterions": [
                {
                    "exact_snippets": "For tumors of the body/tail",
                    "criterion": "tumor location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "body",
                                "tail"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Solid tumor contact with variable anatomy (e.g., accessory right hepatic artery, replaced right hepatic artery, replaced common hepatic artery, and the origin of replaced or accessory artery), and the presence and degree of tumor contact should be noted if present, as it may affect surgical planning",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with variable anatomy (e.g., accessory right hepatic artery, replaced right hepatic artery, replaced common hepatic artery, and the origin of replaced or accessory artery)",
                    "criterion": "solid tumor contact with variable anatomy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the presence and degree of tumor contact should be noted if present",
                    "criterion": "degree of tumor contact",
                    "requirements": [
                        {
                            "requirement_type": "degree",
                            "expected_value": "should be noted if present"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumors of the head with SMA >= 180 degrees, or any celiac abutment, unreconstractable SMV or portal occlusion, or aortic invasion or encasement",
            "criterions": [
                {
                    "exact_snippets": "Tumors of the head with SMA >= 180 degrees",
                    "criterion": "superior mesenteric artery (SMA) involvement",
                    "requirements": [
                        {
                            "requirement_type": "degree of involvement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any celiac abutment",
                    "criterion": "celiac artery abutment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unreconstractable SMV or portal occlusion",
                    "criterion": "unreconstructable superior mesenteric vein (SMV) occlusion",
                    "requirements": [
                        {
                            "requirement_type": "reconstructability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unreconstractable SMV or portal occlusion",
                    "criterion": "portal vein occlusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic invasion or encasement",
                    "criterion": "aortic invasion or encasement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No evidence of metastatic disease as determined by chest computed tomography (CT) scan, abdomen/pelvis computed tomography (CT) scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese) within the 45-day window of study entry or prior to the one cycle of standard of care (SOC) administered before study entry, which is consistent with the standard of care",
            "criterions": [
                {
                    "exact_snippets": "No evidence of metastatic disease",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by chest computed tomography (CT) scan, abdomen/pelvis computed tomography (CT) scan (or magnetic resonance imaging [MRI] with gadolinium and/or manganese)",
                    "criterion": "imaging modality for metastatic disease assessment",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "chest CT",
                                "abdomen/pelvis CT",
                                "MRI with gadolinium and/or manganese"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within the 45-day window of study entry or prior to the one cycle of standard of care (SOC) administered before study entry",
                    "criterion": "timing of imaging for metastatic disease assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 45,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Irrespective of location, all tumors with evidence of nodal metastasis outside of the resection field that are considered unresectable",
            "criterions": [
                {
                    "exact_snippets": "evidence of nodal metastasis outside of the resection field",
                    "criterion": "nodal metastasis outside of the resection field",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "considered unresectable",
                    "criterion": "tumor resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": "unresectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male patients must use a condom during treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male participant should also use a highly effective form of contraception if they are of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Male patients must use a condom during treatment when having sexual intercourse with a pregnant woman or with a woman of childbearing potential.",
                    "criterion": "male patient condom use during treatment",
                    "requirements": [
                        {
                            "requirement_type": "use of condom",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "during treatment"
                        },
                        {
                            "requirement_type": "sexual partner status",
                            "expected_value": [
                                "pregnant woman",
                                "woman of childbearing potential"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Female partners of male participant should also use a highly effective form of contraception if they are of childbearing potential",
                    "criterion": "contraception use by female partners of male participants",
                    "requirements": [
                        {
                            "requirement_type": "contraception type",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "female partner status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Locally-advanced, unresectable disease as defined by NCCN guidelines as follows:",
            "criterions": [
                {
                    "exact_snippets": "Locally-advanced, unresectable disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "local advancement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Borderline resectable PDAC, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Borderline resectable PDAC",
                    "criterion": "borderline resectable pancreatic ductal adenocarcinoma (PDAC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "borderline resectable pancreatic ductal adenocarcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If staging laparoscopy is planned per standard of care, the participant may be asked to consent to the collection of tumor tissue for research",
            "criterions": [
                {
                    "exact_snippets": "If staging laparoscopy is planned per standard of care",
                    "criterion": "staging laparoscopy",
                    "requirements": [
                        {
                            "requirement_type": "planned per standard of care",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the participant may be asked to consent to the collection of tumor tissue for research",
                    "criterion": "consent to collection of tumor tissue for research",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN, OR two consecutive down-trending values for individuals who have undergone biliary stenting prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) ... =< 2.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ... =< 2.5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "two consecutive down-trending values for individuals who have undergone biliary stenting prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening",
                    "criterion": "AST and ALT levels in individuals with prior biliary stenting",
                    "requirements": [
                        {
                            "requirement_type": "trend",
                            "expected_value": "two consecutive down-trending values"
                        },
                        {
                            "requirement_type": "timing of biliary stenting",
                            "expected_value": [
                                "prior to the one month of standard of care chemotherapy allowed by the protocol",
                                "within 4 weeks of screening"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment",
            "criterions": [
                {
                    "exact_snippets": "participants who enroll on trial after having received up to 1 month of standard of care chemotherapy",
                    "criterion": "prior standard of care chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "labs prior to initiation of SOC chemotherapy treatment may be used ... to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study entry",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to SOC chemotherapy",
                            "expected_value": "prior to initiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance should be calculated per institutional standard. For participants with a baseline calculated creatinine clearance below normal institutional laboratory values, a measured baseline creatinine clearance should be determined. Individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance should be calculated per institutional standard",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "per institutional standard"
                        }
                    ]
                },
                {
                    "exact_snippets": "participants with a baseline calculated creatinine clearance below normal institutional laboratory values, a measured baseline creatinine clearance should be determined",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "baseline calculated value",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "normal institutional laboratory values"
                            }
                        },
                        {
                            "requirement_type": "measured value determination",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Individuals with higher values felt to be consistent with inborn errors of metabolism will be considered on a case-by-case basis",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "high value due to inborn errors of metabolism",
                            "expected_value": "case-by-case consideration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* May be waived on a case-by-case basis for patient populations recognized to have normal baseline values below this level",
            "criterions": [
                {
                    "exact_snippets": "patient populations recognized to have normal baseline values below this level",
                    "criterion": "baseline value",
                    "requirements": [
                        {
                            "requirement_type": "normal range",
                            "expected_value": "below this level"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Solid tumor contact with the inferior vena cava",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with the inferior vena cava",
                    "criterion": "solid tumor contact with inferior vena cava",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be deemed fit to undergo planned curative resection as determined by institutional standards",
            "criterions": [
                {
                    "exact_snippets": "Must be deemed fit to undergo planned curative resection as determined by institutional standards",
                    "criterion": "fitness for planned curative resection",
                    "requirements": [
                        {
                            "requirement_type": "fitness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment standard",
                            "expected_value": "institutional standards"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy",
            "criterions": [
                {
                    "exact_snippets": "Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 30 days after the last dose of study therapy",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method adequacy",
                            "expected_value": "adequate"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from first dose of study therapy"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 30,
                                        "unit": "days after last dose of study therapy"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Solid tumor contact with the celiac axis >180 degrees without involvement of the aorta and with an intact and uninvolved gastroduodenal artery, thereby permitting a modified Appleby procedure (although some members of the consensus committee preferred this criterion to be in the unresectable category)",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with the celiac axis >180 degrees",
                    "criterion": "solid tumor contact with celiac axis",
                    "requirements": [
                        {
                            "requirement_type": "degree of contact",
                            "expected_value": {
                                "operator": ">",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without involvement of the aorta",
                    "criterion": "aorta involvement",
                    "requirements": [
                        {
                            "requirement_type": "involvement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "with an intact and uninvolved gastroduodenal artery",
                    "criterion": "gastroduodenal artery",
                    "requirements": [
                        {
                            "requirement_type": "intactness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "involvement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Solid tumor contact with the superior mesenteric vein (SMV) or portal vein of > 180 degrees with contour irregularity of the vein or thrombosis of the vein, but with suitable vessel proximal and distal to the site of involvement, allowing for safe and complete resection and vein reconstruction",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with the superior mesenteric vein (SMV) or portal vein of > 180 degrees",
                    "criterion": "solid tumor contact with SMV or portal vein",
                    "requirements": [
                        {
                            "requirement_type": "degree of contact",
                            "expected_value": {
                                "operator": ">",
                                "value": 180,
                                "unit": "degrees"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "contour irregularity of the vein",
                    "criterion": "contour irregularity of the vein",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thrombosis of the vein",
                    "criterion": "thrombosis of the vein",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suitable vessel proximal and distal to the site of involvement, allowing for safe and complete resection and vein reconstruction",
                    "criterion": "suitability of vessel proximal and distal to site of involvement",
                    "requirements": [
                        {
                            "requirement_type": "suitability for resection and vein reconstruction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cytologic or histologic proof pancreatic ductal carcinoma is required prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "Cytologic or histologic proof pancreatic ductal carcinoma is required",
                    "criterion": "pancreatic ductal carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "cytologic",
                                "histologic"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If a biopsy (e.g., endoscopic ultrasound [EUS]-guided fine needle aspiration [FNA]) is planned per standard of care, the participant may be asked to consent to the additional collection of tumor tissue for research",
            "criterions": [
                {
                    "exact_snippets": "biopsy ... is planned per standard of care",
                    "criterion": "biopsy",
                    "requirements": [
                        {
                            "requirement_type": "planned per standard of care",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "consent to the additional collection of tumor tissue for research",
                    "criterion": "consent to additional tumor tissue collection for research",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment",
            "criterions": [
                {
                    "exact_snippets": "participants who enroll on trial after having received up to 1 month of standard of care chemotherapy",
                    "criterion": "prior standard of care chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "labs prior to initiation of SOC chemotherapy treatment may be used ... to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study entry",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to SOC chemotherapy",
                            "expected_value": "prior to initiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 9 g/dL with no blood transfusion within 28 days of starting treatment (prior to the one month of standard of care chemotherapy allowed by the protocol or within 4 weeks of screening)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no blood transfusion within 28 days of starting treatment",
                    "criterion": "blood transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": "no transfusion within 28 days of starting treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At time of screening, per National Comprehensive Cancer Network (NCCN) criteria, must have either:",
            "criterions": [
                {
                    "exact_snippets": "per National Comprehensive Cancer Network (NCCN) criteria",
                    "criterion": "NCCN criteria",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "At time of screening",
                    "criterion": "time of screening",
                    "requirements": [
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, baseline radiographic imaging performed per institutional guidelines prior to SOC chemotherapy treatment may be used per investigator discretion to fulfill baseline radiographic imaging criteria even if performed > 45 days prior to official study entry.",
            "criterions": [
                {
                    "exact_snippets": "participants who enroll on trial after having received up to 1 month of standard of care chemotherapy",
                    "criterion": "prior standard of care chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "baseline radiographic imaging performed per institutional guidelines prior to SOC chemotherapy treatment may be used ... to fulfill baseline radiographic imaging criteria even if performed > 45 days prior to official study entry",
                    "criterion": "baseline radiographic imaging",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study entry",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "performed per institutional guidelines",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Resectable pancreatic ductal adenocarcinoma (PDAC), defined as no arterial tumor contact (celiac axis [CA], superior mesenteric artery [SMA], or common hepatic artery [CHA]), or",
            "criterions": [
                {
                    "exact_snippets": "Resectable pancreatic ductal adenocarcinoma (PDAC)",
                    "criterion": "pancreatic ductal adenocarcinoma (PDAC)",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no arterial tumor contact (celiac axis [CA], superior mesenteric artery [SMA], or common hepatic artery [CHA])",
                    "criterion": "arterial tumor contact",
                    "requirements": [
                        {
                            "requirement_type": "contact with arteries",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "arteries involved",
                            "expected_value": [
                                "celiac axis (CA)",
                                "superior mesenteric artery (SMA)",
                                "common hepatic artery (CHA)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For tumors of the head or uncinate process:",
            "criterions": [
                {
                    "exact_snippets": "tumors of the head or uncinate process",
                    "criterion": "tumor location",
                    "requirements": [
                        {
                            "requirement_type": "anatomic location",
                            "expected_value": [
                                "head",
                                "uncinate process"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants currently receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) will remain eligible for study participation. In such cases, losartan will not be assigned as part of the study intervention. These participants will continue to receive their ACE inhibitor or ARB per standard-of-care. The ACE inhibitor or ARB type should be recorded as a concomitant medication (including dose and frequency)",
            "criterions": [
                {
                    "exact_snippets": "Participants currently receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) will remain eligible for study participation.",
                    "criterion": "current use of ACE inhibitor or ARB",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "The ACE inhibitor or ARB type should be recorded as a concomitant medication (including dose and frequency)",
                    "criterion": "ACE inhibitor or ARB type, dose, and frequency",
                    "requirements": [
                        {
                            "requirement_type": "documentation as concomitant medication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and the willingness to sign a written informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Solid tumor contact with the common hepatic artery without extension to the celiac axis or hepatic artery bifurcation, allowing for safe and complete resection and reconstruction",
            "criterions": [
                {
                    "exact_snippets": "Solid tumor contact with the common hepatic artery",
                    "criterion": "solid tumor contact with common hepatic artery",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without extension to the celiac axis or hepatic artery bifurcation",
                    "criterion": "tumor extension to celiac axis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without extension to the celiac axis or hepatic artery bifurcation",
                    "criterion": "tumor extension to hepatic artery bifurcation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "allowing for safe and complete resection and reconstruction",
                    "criterion": "resectability and reconstructability",
                    "requirements": [
                        {
                            "requirement_type": "safety and completeness of resection and reconstruction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: On a case by case basis, for participants who enroll on trial after having received up to 1 month of standard of care chemotherapy per Investigator discretion, labs prior to initiation of SOC chemotherapy treatment may be used per Investigator discretion to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry and/or there are more recent labs available from during chemotherapy treatment",
            "criterions": [
                {
                    "exact_snippets": "participants who enroll on trial after having received up to 1 month of standard of care chemotherapy",
                    "criterion": "prior standard of care chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "labs prior to initiation of SOC chemotherapy treatment may be used ... to fulfill screening lab requirements even if performed > 4 weeks prior to official study entry",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study entry",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to SOC chemotherapy",
                            "expected_value": "prior to initiation"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Evidence of metastasis to distant organs (liver, peritoneum, lung, others)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of metastasis to distant organs (liver, peritoneum, lung, others)",
                    "criterion": "metastasis to distant organs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "liver",
                    "criterion": "liver metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "peritoneum",
                    "criterion": "peritoneal metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lung",
                    "criterion": "lung metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements",
            "criterions": [
                {
                    "exact_snippets": "the patient is unlikely to comply with study procedures, restrictions and requirements",
                    "criterion": "compliance with study procedures, restrictions and requirements",
                    "requirements": [
                        {
                            "requirement_type": "likelihood of compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Patients with cardiovascular conditions that are well-controlled in the clinical judgement of the treating oncologist are eligible to participate",
            "criterions": [
                {
                    "exact_snippets": "Personal history of ... syncope of cardiovascular etiology",
                    "criterion": "syncope of cardiovascular etiology",
                    "requirements": [
                        {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Personal history of ... ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation)",
                    "criterion": "ventricular arrhythmia of pathological origin",
                    "requirements": [
                        {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Personal history of ... sudden cardiac arrest",
                    "criterion": "sudden cardiac arrest",
                    "requirements": [
                        {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with cardiovascular conditions that are well-controlled in the clinical judgement of the treating oncologist are eligible to participate",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well-controlled (in the clinical judgement of the treating oncologist)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a history of hypersensitivity reactions to study agents or their excipients. In cases of losartan hypersensitivity, losartan will be omitted and patient may still be eligible to participate",
            "criterions": [
                {
                    "exact_snippets": "history of hypersensitivity reactions to study agents or their excipients",
                    "criterion": "hypersensitivity reactions to study agents or their excipients",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other active malignancy or prior history of malignancy with less than a 90% cure rate in the judgement of the investigators",
            "criterions": [
                {
                    "exact_snippets": "Any other active malignancy",
                    "criterion": "active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of malignancy with less than a 90% cure rate in the judgement of the investigators",
                    "criterion": "prior history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "cure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial therapy",
            "criterions": [
                {
                    "exact_snippets": "Participant is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive ... within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial therapy",
                    "criterion": "expectation to conceive",
                    "requirements": [
                        {
                            "requirement_type": "expectation during trial period",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to ... father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial therapy",
                    "criterion": "expectation to father children",
                    "requirements": [
                        {
                            "requirement_type": "expectation during trial period",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would: interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring adverse events (AEs), or compromise the ability of the patient to give written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would: interfere with evaluation of study treatment or interpretation of participant safety or study results",
                    "criterion": "psychiatric illness or social situations or any condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with evaluation or interpretation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would: ... substantially increase risk of incurring adverse events (AEs)",
                    "criterion": "psychiatric illness or social situations or any condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to substantially increase risk of adverse events",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would: ... compromise the ability of the patient to give written informed consent",
                    "criterion": "psychiatric illness or social situations or any condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to compromise ability to give written informed consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recent major surgery (excluding laparoscopy) within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Patients must be recovered from effects of surgery",
            "criterions": [
                {
                    "exact_snippets": "Recent major surgery (excluding laparoscopy) within 4 weeks prior to starting study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "excluding laparoscopy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Minor surgery within 2 weeks of starting study treatment",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must be recovered from effects of surgery",
                    "criterion": "recovery from surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of previous chemotherapy (other than no more than one cycle of standard systemic chemotherapy), targeted/biologic therapy, or radiation therapy for the treatment of their PDAC",
            "criterions": [
                {
                    "exact_snippets": "History of previous chemotherapy (other than no more than one cycle of standard systemic chemotherapy)",
                    "criterion": "previous chemotherapy for PDAC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of cycles of standard systemic chemotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "cycle"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "targeted/biologic therapy",
                    "criterion": "previous targeted or biologic therapy for PDAC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation therapy for the treatment of their PDAC",
                    "criterion": "previous radiation therapy for PDAC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concomitant use of other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy [hormone replacement therapy is acceptable]), not otherwise allowed in this study. Note: participation in other trials for supportive cancer care (e.g., cancer-related cachexia) interventions is permitted per PI discretion.",
            "criterions": [
                {
                    "exact_snippets": "Concomitant use of other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy [hormone replacement therapy is acceptable]), not otherwise allowed in this study.",
                    "criterion": "concomitant use of other anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hormone replacement therapy is acceptable",
                    "criterion": "hormone replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participation in other trials for supportive cancer care (e.g., cancer-related cachexia) interventions is permitted per PI discretion.",
                    "criterion": "participation in other trials for supportive cancer care interventions",
                    "requirements": [
                        {
                            "requirement_type": "permission",
                            "expected_value": "per PI discretion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medical co-morbidities that are deemed to make risk of surgery unacceptably high as determined by institutional standards",
            "criterions": [
                {
                    "exact_snippets": "Medical co-morbidities that are deemed to make risk of surgery unacceptably high as determined by institutional standards",
                    "criterion": "medical co-morbidities",
                    "requirements": [
                        {
                            "requirement_type": "risk of surgery",
                            "expected_value": "unacceptably high as determined by institutional standards"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}